SSA
ADAP

Schonfeld Strategic Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-349,683
Closed -$1.81M – 2089
2021
Q3 		$1.81M Sell
349,683
-6,170
-2% -$27.7K 0.02% 750
2021
Q2 		$1.52M Buy
355,853
+3,200
+0.9% +$15.5K 0.02% 808
2021
Q1 		$1.87M Buy
+352,653
New +$2.02M 0.02% 683

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's ADAP Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 349,683 shares — an estimated $1.81M sold.

Schonfeld Strategic Advisors first reported a position in ADAP in Q1 2021 and held it in 3 quarters. The position peaked at $1.87M in Q1 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 349,683 Adaptimmune Therapeutics shares in Q4 2021, an estimated $1.81M.
  • Schonfeld Strategic Advisors first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Adaptimmune Therapeutics position peaked at $1.87M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.